|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021400,
umls-concept:C0026336,
umls-concept:C0039195,
umls-concept:C0041361,
umls-concept:C0205263,
umls-concept:C0205369,
umls-concept:C0871261,
umls-concept:C0887910,
umls-concept:C1522424,
umls-concept:C1533691,
umls-concept:C1704632,
umls-concept:C1705822,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
16
|
|
pubmed:dateCreated |
2001-10-12
|
|
pubmed:abstractText |
We investigated influenza virosomes as a TAA-gene delivery system for use in TAA-directed anti-cancer vaccine therapy. An engineered plasmid (GC90) expressing the parathyroid hormone-related peptide (PTH-rP), a protein secreted by prostate and lung carcinoma cells, was included in influenza virosomes (GC90V). The ability of GC90V to elicit a PTH-rP-specific cytotoxic T cell (CTL) response was demonstrated in BALB/c mice immunised with intranasal (i.n.) GC90V+/-adjuvant subcutaneous (s.c.) interleukin-2 (IL-2). A PTH-rP-specific CTL response with antitumour activity was also demonstrated in human peripheral blood mononuclear cells (PBMC) stimulated in vitro with GC90V infected autologous dendritic cells (DC). These results provide a rationale for investigating GC90V in clinical trials of anticancer vaccine therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0959-8049
|
|
pubmed:author |
pubmed-author:CorrealePP,
pubmed-author:CusiM GMG,
pubmed-author:FranciniGG,
pubmed-author:GiorgiGG,
pubmed-author:GluckRR,
pubmed-author:MichellII,
pubmed-author:NenciniCC,
pubmed-author:PetrioliRR,
pubmed-author:PozzessereDD,
pubmed-author:SabatinoMM,
pubmed-author:ValensinP EPE,
pubmed-author:ZurbriggenRR
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
37
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2097-103
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11597390-Administration, Intranasal,
pubmed-meshheading:11597390-Animals,
pubmed-meshheading:11597390-Antigens, Neoplasm,
pubmed-meshheading:11597390-Cancer Vaccines,
pubmed-meshheading:11597390-Cell Culture Techniques,
pubmed-meshheading:11597390-Cytotoxicity, Immunologic,
pubmed-meshheading:11597390-Dendritic Cells,
pubmed-meshheading:11597390-Female,
pubmed-meshheading:11597390-Gene Transfer Techniques,
pubmed-meshheading:11597390-Humans,
pubmed-meshheading:11597390-Influenza A virus,
pubmed-meshheading:11597390-Male,
pubmed-meshheading:11597390-Mice,
pubmed-meshheading:11597390-Mice, Inbred BALB C,
pubmed-meshheading:11597390-Neoplasm Proteins,
pubmed-meshheading:11597390-Parathyroid Hormone-Related Protein,
pubmed-meshheading:11597390-Plasmids,
pubmed-meshheading:11597390-Proteins,
pubmed-meshheading:11597390-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:11597390-Transfection,
pubmed-meshheading:11597390-Tumor Cells, Cultured,
pubmed-meshheading:11597390-Virosomes
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes.
|
|
pubmed:affiliation |
Medical Oncology Division, Medicine School, Siena University, 53100, Siena, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
